News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference
CAMBRIDGE, Mass. , March 17, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today provided an update to
View HTML
Toggle Summary Sarepta Therapeutics to Present Company Overview at the Cowen and Company 37th Annual Health Care Conference
CAMBRIDGE, Mass. , March 02, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics , Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced that it is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston,
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2017-- Sarepta Therapeutics , Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on February 28, 2017 , that were previously approved by the Compensation Committee of its Board of Directors
View HTML
Toggle Summary Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2017-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today reported financial results
View HTML
Toggle Summary Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M
-- Sale of PRV Provides a Significant Infusion of Non-Dilutive Capital -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 21, 2017-- Sarepta Therapeutics , Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today announced it has entered into an agreement to sell its
View HTML
Toggle Summary Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments on February 28, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 15, 2017-- Sarepta Therapeutics , Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, will report fourth quarter and full-year 2016 financial results after the NASDAQ Global Market closes on Tuesday, February 28, 2017.
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2017-- Sarepta Therapeutics , Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on January 31, 2017 , that were previously approved by the Compensation Committee of its Board of Directors
View HTML
Toggle Summary Sarepta Therapeutics Enters into License Agreement with Nationwide Children’s Hospital for Galgt2 Gene Therapy Program
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 10, 2017-- Sarepta Therapeutics , Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered an exclusive license agreement with Nationwide Children’s Hospital, for their Galgt2 gene therapy
View HTML
Toggle Summary Sarepta Therapeutics Enters into Research Agreement and Option Agreement with Nationwide Children’s Hospital for Microdystrophin Gene Therapy Program
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 10, 2017-- Sarepta Therapeutics , Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered a research and option agreement with Nationwide Children’s Hospital on their microdystrophin gene
View HTML
Toggle Summary Sarepta Therapeutics to Present Company Overview at the 2017 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2017-- Sarepta Therapeutics , Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced that it is scheduled to present at the 35 th  Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday,
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.